American Oriental Bioengineering Stock Price, News & Analysis (OTCMKTS:AOBI)

$1.00 0.00 (0.00 %)
(As of 12/11/2017 08:00 AM ET)
Previous Close$1.00
Today's RangeN/A
52-Week Range$1.00 - $5.40
Volume1 shs
Average Volume68 shs
Market Capitalization$70,000.00
P/E RatioN/A
Dividend YieldN/A
Beta-3.17

About American Oriental Bioengineering (OTCMKTS:AOBI)

American Oriental Bioengineering, Inc. is an integrated pharmaceutical company. The Company is engaged in development, manufacture and commercialization of a broad range of pharmaceutical and healthcare products. The Company’s business consists of prescription pharmaceutical products, over-the-counter pharmaceutical products and nutraceutical products. Two flagship prescription pharmaceutical products marketed in China are Shuanghuanglian Lyophilized Injection Powder, or SHL Injection Powder, and Cease Enuresis Soft Gel, or CE Gel. Over-the-counter pharmaceutical products are similar to its prescription pharmaceutical products in that they need approval from the SFDA. Its products in this category include Jinji Series, Cease Enuresis Patch (CE Patch), and Boke Series. Nutraceutical products are intended for the overall well-being. It markets several nutraceutical products in China, which include its soybean peptide based drinks, tablets, powder and instant coffee.

Receive AOBI News and Ratings via Email

Sign-up to receive the latest news and ratings for AOBI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:AOBI
CUSIPN/A
Phone86-451-8666-6601

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares70,000

American Oriental Bioengineering (OTCMKTS:AOBI) Frequently Asked Questions

What is American Oriental Bioengineering's stock symbol?

American Oriental Bioengineering trades on the OTCMKTS under the ticker symbol "AOBI."

Who are some of American Oriental Bioengineering's key competitors?

Who are American Oriental Bioengineering's key executives?

American Oriental Bioengineering's management team includes the folowing people:

  • Shujun Liu, Chairman of the Board, Chief Executive Officer (Age 59)
  • Yanchun Li, Chief Financial Officer, Secretary, Director (Age 43)
  • Xiaopeng Xu, Chief Operations Officer (Age 63)
  • Yan Gao, Chief Accounting Officer (Age 40)
  • Jun Min, Vice President, Director (Age 55)
  • Cosimo J. Patti, Independent Director (Age 62)
  • Xianmin Wang, Independent Director (Age 69)
  • Baiqing Zhang, Independent Director (Age 59)

How do I buy American Oriental Bioengineering stock?

Shares of American Oriental Bioengineering can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is American Oriental Bioengineering's stock price today?

One share of American Oriental Bioengineering stock can currently be purchased for approximately $1.00.

How big of a company is American Oriental Bioengineering?

American Oriental Bioengineering has a market capitalization of $70,000.00.

How can I contact American Oriental Bioengineering?

American Oriental Bioengineering's mailing address is NO 4018 JINTIAN ROAD ANLIAN PLAZA 12F SUITE B02, SHENZHEN F4, 518026. The company can be reached via phone at 86-451-8666-6601 or via email at [email protected]


MarketBeat Community Rating for American Oriental Bioengineering (AOBI)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  22 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  53
MarketBeat's community ratings are surveys of what our community members think about American Oriental Bioengineering and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

American Oriental Bioengineering (OTCMKTS:AOBI) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

American Oriental Bioengineering (OTCMKTS:AOBI) Earnings History and Estimates Chart

Earnings by Quarter for American Oriental Bioengineering (OTCMKTS:AOBI)

American Oriental Bioengineering (OTCMKTS AOBI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2011$0.07$0.05ViewN/AView Earnings Details
5/9/2011$0.04$0.01ViewN/AView Earnings Details
3/14/2011$0.08$0.04ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

American Oriental Bioengineering (OTCMKTS:AOBI) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for American Oriental Bioengineering (OTCMKTS:AOBI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for American Oriental Bioengineering (OTCMKTS AOBI)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

American Oriental Bioengineering (OTCMKTS AOBI) News Headlines

Source:

SEC Filings

American Oriental Bioengineering (OTCMKTS:AOBI) SEC Filings

DateFilerForm TypeView

Social Media

Financials

Financials are not available for this stock.

Chart

American Oriental Bioengineering (OTCMKTS AOBI) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.